{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:35:59Z","timestamp":1790501759253,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012300","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000}}],"reference-count":212,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012300.pub2","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T12:16:45Z","timestamp":1576585005000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatments for preventing recurrence of infection with <i>Pseudomonas aeruginosa<\/i>\n in people with cystic fibrosis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Sally","family":"Palser","sequence":"first","affiliation":[{"name":"School of Medicine, University of Nottingham; Division of Child Health, Obstetrics & Gynaecology (COG); Queen's Medical Centre Derby Road Nottingham UK NG7 2UH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Nottingham; Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine; 1701 E Floor East Block Queens Medical Centre Nottingham NG7 2UH UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F","family":"Nash","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust; West Midlands Adult Cystic Fibrosis Centre; Bordesley Green East Birmingham UK B9 5SS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"University of Toronto; Department of Medicine; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham; Division of Child Health, Obstetrics & Gynaecology (COG); Queen's Medical Centre Derby Road Nottingham UK NG7 2UH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0002|cit2","first-page":"303","article-title":"Pseudomonas aeruginosa serology predicts response to treatment and re-infection in the EPIC clinical study","volume":"46 Suppl 34","author":"Anstead","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcf.2013.07.006","article-title":"Pulmonary exacerbations in CF patients with early lung disease","volume":"13","author":"Anstead","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0004|cit4","first-page":"183","article-title":"Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study","volume":"44 Suppl 32","author":"Hamblett","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"S38","key":"10.1002\/14651858.CD012300.pub2-BIB0005|cit5","first-page":"317","article-title":"Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis","volume":"49","author":"Hamblett","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0006|cit6","first-page":"317","article-title":"Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial","volume":"47 Suppl 35","author":"Hoffman","year":"2012","journal-title":"Pediatric Pulmonolgy"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0007|cit7","first-page":"349","article-title":"Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients","volume":"49","author":"Jorth","year":"2014","journal-title":"Pediatric Pulmonolgy"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0008|cit8","first-page":"304","article-title":"Early evolution of pseudomonas aeruginosa during cystic fibrosis infection","volume":"50 Suppl 41","author":"Jorth","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0009|cit9","first-page":"335","article-title":"Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants & prior antibiotic exposure","volume":"45 Suppl 33","author":"Khan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD012300.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis","volume":"47","author":"Mayer-Hamblett","year":"2012","journal-title":"Pediatric Pulmonolgy"},{"issue":"10","key":"10.1002\/14651858.CD012300.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ppul.22693","article-title":"Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa","volume":"48","author":"Mayer-Hamblett","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0013|cit13","first-page":"146","article-title":"TOBI use in infants and children with early Pseudomonas aeruginosa infection - duration of effect and epic update","volume":"40 Suppl 208","author":"Ramsey","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(10)60210-X","article-title":"Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"9 Suppl 1","author":"Treggiari","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0015|cit15","first-page":"316","article-title":"Early anti-pseudomonal infection in children with CF: study population and conduct of the \"EPIC\" clinical trial","volume":"44 Suppl 32","author":"Treggiari","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD012300.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Archives of Paediatric and Adolescent Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'","volume":"30","author":"Treggiari","year":"2009","journal-title":"Contemporary Clinical Trials"},{"issue":"9","key":"10.1002\/14651858.CD012300.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/adc.67.9.1086","article-title":"The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Comment in: Arch Dis Child 1993 Mar;68(3):432","volume":"67","author":"Brett","year":"1992","journal-title":"Archives of Disease in Childhood"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0007-0971(87)90184-7","article-title":"A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis","volume":"81","author":"Carswell","year":"1987","journal-title":"British Journal of Diseases of the Chest"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1753465815601571","article-title":"Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study","volume":"9","author":"Connett","year":"2015","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0021|cit21","first-page":"333","article-title":"A randomized double-blind, placebo-controlled trial of ciprofloxacin in the treatment of upper respiratory tract infections in children with cystic fibrosis","volume":"49 Suppl 38","author":"Legg","year":"2014","journal-title":"Pediatric Pulmonlogy"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1651-2227.1985.tb10929.x","article-title":"Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin","volume":"74","author":"Conway","year":"1985","journal-title":"Acta Paediatrica Scandinavica"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0023|cit23","unstructured":"Conway SP Miller MG Ramsden CH Littlewood JM Comparison of netilmicin-plus ticarcillin and tobramycin plus ticarcillin in exacerbations of pseudomonas chest infection in cystic fibrosis 12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 Oct; Athens, Greece 1983 271"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0024|cit24","first-page":"R(c)3","article-title":"Evaluation of inhaled colomycin in children with cystic fibrosis","volume":"74","author":"Day","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0025|cit25","unstructured":"Dinwiddie R Hindmarsh P Lock P Azlocillin compared to gentamicin in the treatment of pseudomonas infection in cystic fibrosis 11th European Cystic Fibrosis Conference; 1982; Brussels 1982 229"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0026|cit26","unstructured":"Frederiksen B Hansen A Koch C Hoiby N Delay of recurrence of Pseudomonas aeruginosa in patients with cystic fibrosis with inhaled colistin and oral ciproxin: a comparison between 3 weeks and 3 months of treatment Pediatric Pulmonology 1997 288"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0027|cit27","unstructured":"Frederiksen B Pressler T Koch C Hoiby N Endpoints for evaluating early anti-pseudomonal treatment: changes in pseudomonas prevalence and in pulmonary function Pediatric Pulmonology 2003 334"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0028|cit28","first-page":"246","article-title":"Effect of aerosolised rhDnase (Pulmozyme\u00ae) on pulmonary infections in CF: an open randomised study","volume":"Suppl 20","author":"Frederiksen","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD012300.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/08035250600752466","article-title":"Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis","volume":"95","author":"Frederiksen","year":"2006","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0030|cit30","first-page":"354","article-title":"Evaluation of antibiotic therapy in patients with cystic fibrosis","volume":"76","author":"Huang","year":"1979","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0031|cit31","unstructured":"Huang NN Palmer J Braverman S Keith HH Schidlow D Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study 23rd Annual Meeting Cystic Fibrosis Club Abstracts; 1982 May 14; Washington D.C 1982 124"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60158-2","article-title":"Eradication of Pseudomonas aeruginosa in adults with CF","volume":"8 Suppl 2","author":"Kenny","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0033|cit33","unstructured":"Knight RK Batten JC Mearns M A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum 9th Meeting European Working Group for Cystic Fibrosis; 1979 Jun 12-13; Noordwijkerhout, the Netherlands 1979 52"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(14)60179-X","article-title":"Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial","volume":"13 Suppl 2","author":"Chiron","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60084-7","article-title":"Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients","volume":"9 Suppl 1","author":"Geller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60100-8","article-title":"Microbiological and clinical response to tobramycin inhalation powder (TIP\u2122) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection","volume":"10 Suppl 1","author":"Geller","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4187\/respcare.02264","article-title":"Tobramycin inhalation powder in cystic fibrosis patients: response by age group","volume":"59","author":"Geller","year":"2014","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60083-5","article-title":"Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa)","volume":"9 Suppl 1","author":"Konstan","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0039|cit39","first-page":"303","article-title":"Tobramycin inhalation powder (TIP) versus tobramycin inhalation solution (TOBI\u00ae): the EAGER trial","volume":"45 Suppl 33","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0041|cit41","first-page":"283","article-title":"Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial","volume":"48 Suppl 36","author":"Nasr","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(11)60345-7","article-title":"Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1569-1993(11)60336-6","article-title":"Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcf.2012.04.007","article-title":"Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis","volume":"11","author":"Regnault","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcf.2007.07.001","article-title":"Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis","volume":"7","author":"Latzin","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0022-3476(79)80785-4","article-title":"A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis","volume":"95","author":"Loening Baucke","year":"1979","journal-title":"Journal of Pediatrics"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD012300.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1203\/00006450-197804001-00795","article-title":"Cephalexin in cystic fibrosis: a placebo-controlled study","volume":"12","author":"Loening-Baucke","year":"1978","journal-title":"Pediatric Research"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0048|cit48","unstructured":"Loening-Bauke V Mischler EH Myers MG Cephalexin compared to placebo in the management of patients with cystic fibrosis 19th Cystic Fibrosis Club Abstracts; 1978 1978 69"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/adc.55.8.604","article-title":"Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis","volume":"55","author":"Martin","year":"1980","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0050|cit50","first-page":"296","article-title":"Reduction of pulmonary hospitalizations during a randomized, controlled, open-label study of tobramycin solution for inhalation in young CF patients with mild lung disease","volume":"Suppl 25","author":"Anbar","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0051|cit51","first-page":"S22","article-title":"Reduction in pulmonary hospitalizations during a randomized, controlled, open-label study of tobramycin solution for inhalation in young CF patients with mild lung disease","volume":"2 Suppl 1","author":"Colin","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ppul.20097","article-title":"Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease","volume":"38","author":"Murphy","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0053|cit53","unstructured":"Cystic Fibrosis Foundation Inhaled ciprofloxacin www.cff.org (www.cff.org\/clinicaltrials)"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0054|cit54","first-page":"296","article-title":"Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis- a phase IIB study of ciprofloxacin dry powder for inhalation (DPI)","volume":"46 Suppl 34","author":"Dorkin","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0055|cit55","unstructured":"NCT00645788 Study to evaluate the safety and efficacy of ciprofloxacin (inhaled) in patients with cystic fibrosis clinicaltrials.gov\/show\/NCT00645788"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"495-502. Online","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0059|cit59","unstructured":"NCT01180634 MP-376 (Aeroquin\u2122, Levofloxacin for Inhalation) in patients with cystic fibrosis clinicaltrials.gov\/show\/NCT01180634"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0060|cit60","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0061|cit61","unstructured":"NCT01400750 Comparison of 2 treatment regimens for eradication of p aeruginosa infection in children with cystic fibrosis clinicaltrials.gov\/show\/NCT01400750"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012300.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(08)60246-5","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ ciprofloxacin","volume":"7 Suppl 2","author":"Proesmans","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD012300.pub2-BIB0063|cit63","first-page":"321","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ciprofloxacin","volume":"44 Suppl 32","author":"Proesmans","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(11)60119-7","article-title":"Eradication of recent pseudomonas aeruginosa infection: TOBI versus Colistineb\u00ae\/ ciprofloxacin","volume":"10 Suppl 1","author":"Proesmans","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0066|cit66","first-page":"273","article-title":"Economic analysis of hospitalization and home IV anti-pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI\u00ae)","volume":"Suppl 17","author":"Birnbaum","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S1569-1993(02)00003-6","article-title":"The long-term use of inhaled tobramycin in patients with cystic fibrosis","volume":"1 Suppl 2","author":"Bowman","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD012300.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0069|cit69","unstructured":"Casey S Ramsey B Borowitz D Nutritional benefits of chronic intermittent Pseudomonas aeruginosa suppression with tobramycin solution for inhalation in adolescents 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 172"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0070|cit70","first-page":"339","article-title":"Mortality rates during 2 years of treatment with intermittent inhaled tobramycin (TOBI) in CF","volume":"Suppl 19","author":"Enger","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0071|cit71","unstructured":"Fiel S VanDevanter D Yu X Effect of tobramycin solution for inhalation on pulmonary function decline rates in exacerbating and stable CF patients 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria 2001 P195"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0072|cit72","first-page":"1545","article-title":"Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients","volume":"16 Suppl 31","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0074|cit74","first-page":"283","article-title":"Epidemiology of Stenotrophomonas maltophilia culture in cystic fibrosis (CF) patients during the tobramycin solution for inhalation (TOBI\u00ae) study","volume":"Suppl 20","author":"Graff","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0075|cit75","first-page":"130","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"135","author":"Hazinski","year":"1999","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0076|cit76","first-page":"305","article-title":"Peripheral white blood cell count as a surrogate marker for progression of lung disease in cystic fibrosis","volume":"Suppl 22","author":"Konstan","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0300-2977(99)90288-7","article-title":"Who benefits more? An age-stratified analysis of lung function and weight gain in CF patients using inhaled tobramycin","volume":"54 Suppl","author":"Kylstra","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0149-2918(00)87985-0","article-title":"Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis","volume":"22","author":"LeLorier","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD012300.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/315312","article-title":"Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment","volume":"181","author":"MacLeod","year":"2000","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0081|cit81","first-page":"243","article-title":"Who benefits more? An analysis of FEV1 and weight in adolescent (age 13-<18) CF patients using inhaled tobramycin (TOBI)","volume":"Suppl 19","author":"Moss","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD012300.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"107S","DOI":"10.1378\/chest.120.3_suppl.107S","article-title":"Administration of aerosolized antibiotics in cystic fibrosis patients","volume":"120","author":"Moss","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0084|cit84","first-page":"243","article-title":"Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients","volume":"Suppl 19","author":"Nickerson","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0085|cit85","first-page":"273","article-title":"Seasonality of hospitalization for pulmonary exacerbations and lower respiratory tract infections in Phase III tobramycin solution for inhalation (TOBI\u00ae) trials","volume":"Suppl 17","author":"Otto","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0300-2977(99)90290-5","article-title":"Treatment for exacerbation only does not arrest progressive lung function decline in CF","volume":"54 Suppl","author":"Quan","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0087|cit87","unstructured":"Quittner A Gordon D Yu X Convergence of quality of life assessments and clinical outcomes in patients enrolled in the tobramycin solution for inhalation (TSI) trials 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria 2001 P326"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0089|cit88","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ppul.10074","article-title":"Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"33","author":"Quittner","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0088|cit89","first-page":"349","article-title":"Longitudinal changes in global ratings of quality of life for patients in the tobramycin solution for inhalation (TSI) trials","volume":"Suppl 22","author":"Quittner","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0090|cit90","first-page":"137","article-title":"Safety and efficacy of Tobramycin Solution for Inhalation in patients with cystic fibrosis: The results of two phase III placebo controlled clinical trials","volume":"Suppl 14","author":"Ramsey","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0091|cit91","unstructured":"Ramsey BW Bowman MC Montgomery AB Smith AR TOBI Study Group Design of phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos, Switzerland 1997 144"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0092|cit92","unstructured":"Ramsey BW Bowman MC Vasiljev-KM Smith AR TOBI Study Group Results of phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos, Switzerland 1997 144"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0095|cit95","first-page":"291","article-title":"Nebulised high dose Tobramycin (TOBI) in adolescents with cystic fibrosis","volume":"Suppl 22","author":"Taylor","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0096|cit96","first-page":"298","article-title":"Effect of tobramycin solution for inhalation (TOBI\u00ae) on long term rates of lung function decline in Pseudomonas aeruginosa infected cystic fibrosis (CF) patients with mild to moderate lung disease","volume":"Suppl 20","author":"VanDevanter","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0097|cit97","unstructured":"VanDevanter D Yu X Konstan MW Effect of tobramycin solution for inhalation on circulating white blood cell counts in exacerbating and stable CF patients 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria 2001 P172"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0098|cit98","unstructured":"ISRCTN80955954 Elite study: the microbiological efficacy and safety of two treatment regimens of inhaled tobramycine nebuliser solution (TNS) for the treatment of early onset pseudomonas aeruginosa lower respiratory tract infection in subjects with cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN80955954"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0099|cit99","unstructured":"NTR377 ELITE study www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR377"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0100|cit100","first-page":"318","article-title":"Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the Elite study","volume":"41 Suppl 29","author":"Ratjen","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(06)80085-8","article-title":"Safety of inhaled tobramycin nebuliser solution for treatment of early pseudomonas aeruginosa infection: first results from the ELITE study","volume":"5 Suppl","author":"Ratjen","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0103|cit102","first-page":"319","article-title":"Short and long-term efficacy of inhaled tobramycin in early P. Aeruginosa infection: the ELITE study","volume":"43 Suppl 31","author":"Ratjen","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0102|cit103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60098-3","article-title":"Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection; the ELITE study","volume":"7 Suppl 2","author":"Ratjen","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0105|cit105","first-page":"S1","article-title":"TOBI\u00ae for eradication of early P. aeruginosa infection in paediatric cystic fibrosis patients: the EARLY study","volume":"15 Suppl 1","author":"Ratjen","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Ratjen F Moeller A McKinney ML Asherova I Alon N Maykut R Eradication of early P. aeruginosa infection in children <7years of age with cystic fibrosis: the early study Journal of Cystic Fibrosis 2019 78 85 10.1016\/j.jcf.2018.04.002","DOI":"10.1016\/j.jcf.2018.04.002"},{"issue":"10","key":"10.1002\/14651858.CD012300.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/BF01963771","article-title":"Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin","volume":"8","author":"Schaad","year":"1989","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0108|cit108","first-page":"335","article-title":"A clinically-embedded trial to evaluate the efficacy of interventions for pre-pseudomonal pathogens","volume":"48 Suppl 36","author":"Singh","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD012300.pub2-BIB0109|cit109","first-page":"348","article-title":"Semi-automated rep-pcr genotyping of pseudomonas aeruginosa in Italian CF patients in eradication therapy","volume":"45","author":"Cariani","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 36","key":"10.1002\/14651858.CD012300.pub2-BIB0110|cit110","first-page":"288","article-title":"Anti- P. aeruginosa antibodies and microbiological outcome in patients treated with early eradication therapy","volume":"48","author":"Dolce","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0111|cit111","unstructured":"EUCTR2008-006502-42-IT Early antibiotic treatment in pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols - #FFC17\/2007 www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-006502-42-IT"},{"issue":"S33","key":"10.1002\/14651858.CD012300.pub2-BIB0112|cit112","first-page":"337","article-title":"Pseudomonas aeruginosa eradication in cystic fibrosis: preliminary data from a randomized multicenter study of two different early antibiotic treatment protocols","volume":"45 Suppl 33","author":"Taccetti","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0113|cit113","first-page":"317","article-title":"Pseudomonas aeruginosa microbiological status and emergence of other pathogens after early eradication treatment in cystic fibrosis: a post-trial follow-up","volume":"46 Suppl 34","author":"Taccetti","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"S32","key":"10.1002\/14651858.CD012300.pub2-BIB0114|cit114","first-page":"354","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomized multicenter study of two different protocols","volume":"44 Suppl 32","author":"Taccetti","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 34","key":"10.1002\/14651858.CD012300.pub2-BIB0115|cit115","first-page":"317","article-title":"Pseudomonas aeruginosa eradication in cystic fibrosis: final results of a randomized multicenter study of two different early antibiotic treatment protocols","volume":"46","author":"Taccetti","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0117|cit117","first-page":"328","article-title":"Is early eradication treatment against P.aeruginosa associated with the emergence of other non-fermenter gram negatives","volume":"48 Suppl 36","author":"Taccetti","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0118|cit118","first-page":"5","article-title":"Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways","volume":"14 Suppl 1","author":"Taccetti","year":"2019","journal-title":"Multidisciplinary Respiratory Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012300.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with\u00a0cystic\u00a0fibrosis: a randomised multicentre study comparing two different protocols","volume":"67","author":"Taccetti\u00a0G","year":"2012","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012300.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(10)60111-7","article-title":"Epidemiology of first\/new Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"9","author":"Zavataro","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(19)30118-3","article-title":"Comparative genomics study of a set of Pseudomonas aeruginosa isolates from the TORPEDO-CF trial","volume":"18 Suppl 1","author":"Cazares","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0122|cit122","unstructured":"EUCTR2009-012575-10-SE Trial of optimal therapy for pseudomonas eradication in cystic fibrosis - TORPEDO-CF www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-012575-10-SE 2016"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0123|cit123","unstructured":"ISRCTN02734162 Trial of optimal therapy for pseudomonas eradication in cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN02734162"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0126|cit124","unstructured":"Langton Hewer S TORPEDO-CF www.controlled-trials.com\/ISRCTN02734162\/torpedo-cf"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0124|cit125","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1569-1993(17)30428-9","article-title":"TORPEDO-CF-completion of recruitment to trial of optimal regimen for eradication of new infection with Pseudomonas aeruginosa","volume":"16 Suppl 1","author":"Langton Hewer","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD012300.pub2-BIB0125|cit126","first-page":"294","article-title":"Torpedo-CF - trial of optimal therapy for pseudomonas eradication in cystic fibrosis","volume":"53","author":"Langton Hewer","year":"2018","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(19)30117-1","article-title":"Effectiveness of IV compared to oral eradication therapy of Pseudomonas aeruginosa in cystic fibrosis: multicentre randomised controlled trial (TORPEDO-CF)","volume":"18 Suppl 1","author":"Langton Hewer","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD012300.pub2-BIB0128|cit128","first-page":"302","article-title":"Intravenous vs oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (Torpedo-CF): a randomised controlled trial","volume":"54","author":"Smyth","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0129|cit129","unstructured":"University of Liverpool Clinical Trials Research Centre TORPEDO-CF www.controlled-trials.com\/ISRCTN02734162\/torpedo-cf"},{"issue":"8769","key":"10.1002\/14651858.CD012300.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0131|cit131","first-page":"248","article-title":"Prevention of chronic colonization with Pseudomonas aeruginosa in patients with CF by early treatment with ciprofloxacin and colistin aerosol inhalations","volume":"9 Suppl 5","author":"Valerius","year":"1990","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0132|cit132","first-page":"255","article-title":"Prevention of chronic pseudomonas aeruginosa infection by early inhalation therapy with tobramycin","volume":"Suppl 10","author":"Ratjen","year":"1994","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD012300.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for early Pseudomonas infection in cystic fibrosis: the Optimize randomized trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Erratum: azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial","volume":"199","author":"Mayer-Hamblett","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0136|cit136","unstructured":"NCT02054156 Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis clinicaltrials.gov\/show\/NCT02054156"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0137|cit137","first-page":"380","article-title":"Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial","volume":"52 Suppl 47","author":"Ramsey","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0138|cit138","unstructured":"EUCTR2011-000801-39-SE Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens\u2019 eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosis (first received 13 December 2011)"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0139|cit139","first-page":"343","article-title":"Anti-pseudomonas IGY ready for phase III","volume":"45 Suppl 33","author":"Kollberg","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(11)60110-0","article-title":"Phase III study (IMPACTT) on anti-pseudomonas IgY","volume":"10 Suppl 1","author":"Larsson","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0141|cit141","unstructured":"NCT01455675 Efficacy study of igy (antibody against pseudomonas) in cystic fibrosis patients clinicaltrials.gov\/show\/nct01455675"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(19)30190-0","article-title":"Clinical study to evaluate an anti-Pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011-000801-39)","volume":"18","author":"Schuster","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD012300.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K","article-title":"Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis","volume":"21","author":"Armstrong","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1183\/09031936.00072808","article-title":"Dental units as infection sources of Pseudomonas aeruginosa","volume":"32","author":"Barben","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/318075","article-title":"Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"9028","key":"10.1002\/14651858.CD012300.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(96)05169-0","article-title":"Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1440-1754.1994.tb00605.x","article-title":"An outbreak of pneumocystis carinii pneumonia in children with malignancy","volume":"30","author":"Cheung","year":"1994","journal-title":"Journal of Paediatrics and Child Health"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2180-8-105","article-title":"A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis","volume":"8","author":"Clifton","year":"2008","journal-title":"BMC Microbiology"},{"issue":"11","key":"10.1002\/14651858.CD012300.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"e27784","DOI":"10.1371\/journal.pone.0027784","article-title":"Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study","volume":"6","author":"Collaco","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/thx.51.1.29","article-title":"Compliance with treatment in adult patients with cystic fibrosis","volume":"51","author":"Conway","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0151|cit151","unstructured":"CF Foundation About Cystic Fibrosis www.cff.org\/What-is-CF\/About-Cystic-Fibrosis\/"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0152|cit152","unstructured":"Cystic Fibrosis Foundation [US] Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2017-Patient-Registry-Annual-Data-Report.pdf"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0153|cit153","unstructured":"UK Cystic Fibrosis Trust Antibiotic Treatment for Cystic Fibrosis - 3rd edition. Report of the UK Cystic Fibrosis Trust Antibiotic Group www.cysticfibrosis.org.uk\/media\/82010\/antibiotic-treatment-for-cystic-fibrosis-may-09.pdf"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0154|cit154","unstructured":"Cystic Fibrosis Trust About CF, frequently asked questions www.cysticfibrosis.org.uk\/about-cf\/frequently-asked-questions#na"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0155|cit155","unstructured":"Cystic Fibrosis Trust UK Cystic Fibrosis Registry Annual Data Report 2017 www.cysticfibrosis.org.uk\/the-work-we-do\/uk-cf-registry\/reporting-and-resources"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0156|cit156","unstructured":"Deeks JJ Higgins JP Altman DG on behalf of the CSMG editor(s) Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1183\/09031936.00099506","article-title":"Cystic fibrosis mortality and survival in the UK: 1947-2003","volume":"29","author":"Dodge","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"e002709","DOI":"10.1136\/bmjopen-2013-002709","article-title":"Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis","volume":"3","author":"Dwan","year":"2013","journal-title":"BMJ Open"},{"issue":"8","key":"10.1002\/14651858.CD012300.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ijmm.2010.08.010","article-title":"Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"300","author":"D\u00f6ring","year":"2010","journal-title":"International Journal of Medical Microbiology"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD012300.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thorax.55.11.946","article-title":"Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis","volume":"55","author":"Gee","year":"2000","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/oxfordjournals.bmb.a072585","article-title":"Microbiology of lung infection in cystic fibrosis","volume":"48","author":"Govan","year":"1992","journal-title":"British Medical Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ppul.10019","article-title":"Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study","volume":"33","author":"Heinzl","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD012300.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clinical Infectious Disease"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0165|cit165","unstructured":"Higgins JP Deeks JJ editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0166|cit166","unstructured":"Higgins JP Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0167|cit167","unstructured":"Higgins JP Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group editor(s) Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8","key":"10.1002\/14651858.CD012300.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijmm.2010.08.008","article-title":"Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung","volume":"300","author":"Hogardt","year":"2010","journal-title":"International Journal of Medical Microbiology"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jcf.2013.12.002","article-title":"Rate of improvement of CF life expectancy exceeds that of general population--observational death registration study","volume":"13","author":"Hurley","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2005.05.018","article-title":"Eradication of early Pseudomonas aeruginosa infection","volume":"4 Suppl 2","author":"H\u00f8iby","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0171|cit171","first-page":"2","article-title":"What researchers mean by Primary, Secondary and Tertiary Prevention","volume":"Spring 2015","author":"Institute for Work and Health","year":"2015","journal-title":"At Work"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0195-6701(97)90117-1","article-title":"Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment","volume":"36","author":"Jensen","year":"1997","journal-title":"Journal of Hospital Infection"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/thx.47.2.109","article-title":"Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark","volume":"47","author":"Johansen","year":"1992","journal-title":"Thorax"},{"issue":"9281","key":"10.1002\/14651858.CD012300.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(01)05714-2","article-title":"Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic","volume":"358","author":"Jones","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/thorax.58.6.525","article-title":"Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak","volume":"58","author":"Jones","year":"2003","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0176|cit176","first-page":"S31","article-title":"Secular trends in Pseudomonas aeruginosa acquisition in the United Kingdom: a registry study","volume":"14 Supp 1","author":"Jones","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00248-006-9059-3","article-title":"Isolation of Pseudomonas aeruginosa from open ocean and comparison with freshwater, clinical, and animal isolates","volume":"53","author":"Khan","year":"2007","journal-title":"Microbial Ecology"},{"issue":"8","key":"10.1002\/14651858.CD012300.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/thoraxjnl-2014-205213","article-title":"Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis","volume":"69","author":"Knibbs","year":"2014","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ppul.10290","article-title":"Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study","volume":"35","author":"Kollberg","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"134-9, 139 e1","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009.abs","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub5","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton Hewer","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"438517","DOI":"10.1155\/2015\/438517","article-title":"Pseudomonas aeruginosa acquisition in cystic fibrosis patients in context of otorhinolaryngological surgery or dentist attendance: case series and discussion of preventive concepts","volume":"2015","author":"Mainz","year":"2015","journal-title":"Case Reports in Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD012300.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0185|cit185","unstructured":"Microsoft Corporation MS Excel 2016"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ppul.1121","article-title":"Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization","volume":"32","author":"Munck","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00944_1.x","article-title":"British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011","volume":"12 Suppl 2","author":"Nelson","year":"2011","journal-title":"HIV Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012300.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1067\/mpd.2001.112897","article-title":"Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"138","author":"Nixon","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"12","key":"10.1002\/14651858.CD012300.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"e012303","DOI":"10.1136\/bmjopen-2016-012303","article-title":"Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study","volume":"6","author":"Palser","year":"2016","journal-title":"BMJ Open"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jhin.2004.09.018","article-title":"Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces","volume":"59","author":"Panagea","year":"2005","journal-title":"Journal of Hospital Infection"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jcf.2016.02.014","article-title":"Extensive cultivation of soil and water samples yields various pathogens in patients with cystic fibrosis but not Burkholderia multivorans","volume":"15","author":"Peeters","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD012300.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1462-2920.2005.00776.x","article-title":"Global Pseudomonas aeruginosa biodiversity as reflected in a Belgian river","volume":"7","author":"Pirnay","year":"2005","journal-title":"Environmental Microbiology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0193|cit193","first-page":"13","article-title":"Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis","volume":"79 Suppl 12","author":"Pitt","year":"1986","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012300.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"E483","DOI":"10.1111\/1469-0691.12272","article-title":"Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis","volume":"19","author":"Psoter","year":"2013","journal-title":"Clinical Microbiology and Infection"},{"issue":"3","key":"10.1002\/14651858.CD012300.pub2-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1513\/AnnalsATS.201408-400OC","article-title":"Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis","volume":"12","author":"Psoter","year":"2015","journal-title":"Annals of the American Thoracic Society"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/ajrccm\/144.2.331","article-title":"Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients","volume":"144","author":"Ramsey","year":"1991","journal-title":"American Review of Respiratiry Disease"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0198|cit198","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/JCM.01324-09","article-title":"Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling","volume":"48","author":"Rogers","year":"2010","journal-title":"Journal of Clinical Microbiology"},{"issue":"6","key":"10.1002\/14651858.CD012300.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","article-title":"The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012300.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/676882","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35 Suppl 1","author":"Saiman","year":"2014","journal-title":"Infection Control & Hospital Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012300.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1183\/09031936.00088907","article-title":"Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients","volume":"31","author":"Schelstraete","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcf.2009.11.006","article-title":"Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients","volume":"9","author":"Schelstraete","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0205|cit205","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0206|cit206","unstructured":"Smyth A The Core Outcome Set for CF (COST-CF) www.comet-initiative.org\/studies\/details\/882?result=true"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0195-6701(87)90089-2","article-title":"Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis","volume":"9","author":"Speert","year":"1987","journal-title":"Journal of Hospital Infection"},{"issue":"2","key":"10.1002\/14651858.CD012300.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/jcm.28.2.188-194.1990","article-title":"Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis","volume":"28","author":"Speert","year":"1990","journal-title":"Journal of Clinical Microbiology"},{"issue":"7","key":"10.1002\/14651858.CD012300.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1164\/rccm.2203011","article-title":"Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada","volume":"166","author":"Speert","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0210|cit210","unstructured":"StataCorp LLC Stata Statistical Software: Release 16 2019"},{"key":"10.1002\/14651858.CD012300.pub2-BIB0211|cit211","unstructured":"Sterne JA Egger M Moher D on behalf of the Cochrane Bias Methods Group editor(s) Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 updated March 2011. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD012300.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ppul.23036","article-title":"Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis","volume":"50","author":"Zemanick","year":"2015","journal-title":"Pediatric Pulmonology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012300.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T08:04:43Z","timestamp":1681459483000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012300.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":212,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012300.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]}}}